Blog - CADDAC

20/01/2017 - CADDAC National Director

Are we Prescribing too Many Antipsychotic Medications for Children with ADHD?

A recent study by the Institute for Clinical Evaluative Sciences found almost 12 per cent of children and youth with attention deficit hyperactivity disorder, or ADHD, were prescribed antipsychotics like Risperdal, Zyprexa and Seroquel. Since the study

23/12/2016 - Juanita Beaudry

New BC PharmaCare Coverage Discriminatory to Adults with ADHD

New BC PharmaCare Coverage Discriminatory to Adults with ADHD On April 18th BC PharmaCare announced that it was expanding its existing coverage of medications for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the paediatric popula

23/12/2016 - Juanita Beaudry

Education Ministry Special Education Guidelines Will Recognize ADHD under the Learning Disorder Category

Education Ministry Special Education Guidelines Will Recognize ADHD under the Learning Disorder Category A new Huffington Post article is talking about changes coming to the BC Special Education Guidelines that will allow students with ADHD, who presen

23/12/2016 - Juanita Beaudry

Follow–up from Health Canada regarding Generic Forms of Concerta

This past week, a follow-up letter was received from Marion Law, the Director General of Health Canada’s Therapeutic Products Directorate (TPD) addressing discussions during the Oct 31 meeting with Janssen, CADDAC and ADHD medical experts. The letter

23/12/2016 - Juanita Beaudry

Advocacy Campaign

ADHD Advocacy One of our primary goals is advocating for individuals with ADHD. However doing so on an individual basis across Canada is not only impossible, but unproductive when looking at the bigger picture. "How can this be?" you might ask. Helping

21/12/2016 - CADDAC National Director

Follow–up from Health Canada regarding Generic Forms of Concerta

This past week, a follow-up letter was received from Marion Law, the Director General of Health Canada’s Therapeutic Products Directorate (TPD) addressing discussions during the Oct 31 meeting with Janssen, CADDAC and ADHD medical experts. The letter